Talk:AIM ImmunoTech

This is the talk page for discussing improvements to the AIM ImmunoTech article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

This article is of interest to the following WikiProjects:

Pennsylvania Stub‑class Low‑importance

	Pennsylvania portal This article is within the scope of WikiProject Pennsylvania, a collaborative effort to improve the coverage of Pennsylvania on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PennsylvaniaWikipedia:WikiProject PennsylvaniaTemplate:WikiProject PennsylvaniaPennsylvania articles
Stub	This article has been rated as Stub-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Philadelphia Stub‑class Low‑importance

	Philadelphia portal This article is within the scope of WikiProject Philadelphia, a collaborative effort to improve the coverage of Philadelphia on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PhiladelphiaWikipedia:WikiProject PhiladelphiaTemplate:WikiProject PhiladelphiaPhiladelphia articles
Stub	This article has been rated as Stub-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Pharmacology Stub‑class Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Stub	This article has been rated as Stub-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Companies Stub‑class Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Stub This article has been rated as Stub-class on Wikipedia's content assessment scale.

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

Proposed text

It is requested that edits be made to the following semi-protected pages:

D (edit · history · last · links · protection log)
ADV (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

Information on current page is not very informative or helpful. Paragraphs three and four had to do with complicated derivative accounting issues which occurred eleven years ago and is irrelevant.

Proposed text:

Hemispherx Biopharma, Inc. is a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Hemispherx first formed in 1966 and in the early 1970s was doing contract research for the National Institutes of Health. Since then, Hemispherx has established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases.

Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic Ampligen®.

Alferon N Injection® is approved in the United States for a category of STD infection, and Ampligen® represents an experimental RNA being developed for globally important viral diseases and disorders of the immune system. Hemispherx' platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Alferon® LDO (Low Dose Oral) is a formulation under development targeting influenza.

Alferon N Injection® has also received approval in Argentina (pending brand name “Naturaferon”) for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.

Ampligen® is in late stage clinical trials in the United States and has received approval from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for commercial sale of rintatolimod (U.S. tradename: Ampligen®, proposed tradename for Argentina: Rintamod®) in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA, is Hemispherx’s exclusive commercial partner for Ampligen and Alferon N Injection in Argentina and other possible Latin America countries.

Hemispherx has worldwide patents comprising its core intellectual property estate.

Hemispherx wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

BluebirdHill5 (talk) 21:55, 4 April 2017 (UTC) Hemispherx Biopharma, Inc.[reply]

Not done the content proposed is promotional and not neutral in tone, it is also sourced to their own website, we have no interest in what they say about them selves, we only summarise what reliable, independent published sources say about the topic. Theroadislong (talk) 14:43, 5 May 2017 (UTC)[reply]

It is requested that edits be made to the following semi-protected pages:

D (edit · history · last · links · protection log)
ADV (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

{{Request edit}} Information on the current page is not very informative or helpful. Paragraphs three and four had to do with complicated derivative accounting issues which occurred eleven years ago and is irrelevant. Per the comments from Theroadislong, I have revised description from a third-party source:

Hemispherx Biopharma, Inc. (NYSE MKT: HEB) is a specialty pharmaceutical company engaged in the clinical development of new drug therapies to address unmet medical needs. The Company has spent more than two decades of research and development on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. Hemispherx' platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx’s products include Alferon N Injection® and the experimental therapeutic Ampligen®.

Alferon N Injection® is a natural interferon (IFN) product and is approved in the United States for the intralesional treatment of external, refractory, or recurring genital warts (i.e., HPV) in adults over 18 years of age. Alferon N Injection® has also received approval in Argentina (pending brand name “Naturaferon”) for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. Alferon® LDO (Low Dose Oral) is a formulation under development targeting influenza.

Ampligen® represents an experimental double-stranded RNA molecule being developed for globally important viral diseases and disorders of the immune system. Hemispherx has been administered over 90,000 doses of Ampligen® to more than 800 adults through 13 clinical trials and has reported that the drug to be generally well tolerated. Of the 13 studies, nine of the studies have occurred in patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Ampligen® received approval in August 2016 from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for commercial sale of rintatolimod (U.S. tradename: Ampligen®, proposed tradename for Argentina: Rintamod®) in the Argentine Republic for the treatment of severe ME/CFS.

Ampligen® is available in Europe and Turkey through myTomorrows, a Netherlands based company, who is managing an Early Access Program to supply Ampligen® for the treatment of ME/CFS and pancreatic cancer to patients with an unmet medical need, as well as, U.S. based compassionate care programs such as AMP-511.

Hemispherx has worldwide patents comprising its core intellectual property estate. Hemispherx is headquartered in Philadelphia Pennsylvania with research and manufacturing facilities in New Brunswick New Jersey.

^[1]

BluebirdHill5 (talk) 22:01, 26 May 2017 (UTC) [reply]

The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.

BluebirdHill5 (talk · contribs)

References

^ Crystal Research Associates https://www.crystalra.com/research-library/hemispherx

[1] Crystal Research Associates https://www.crystalra.com/research-library/hemispherx

[1]